

Special Issue

The 10th International MDM2 Workshop—Opening Up New Avenues for MDM2 and p53 Research

Message from the Guest Editors

This Special Issue of *Cancers* will focus on the E3 ubiquitin ligase MDM2 in a special collaboration with the 10th International MDM2 Workshop

(<https://www.10thmdm2.jp>), taking place in Tokyo, Japan, on 15–18 October 2023. MDM2 (Murine Double Minute 2) is a RING-domain-containing E3 ubiquitin ligase and is the most critical negative regulator of p53. At the molecular level, MDM2 functions as a dimer, most notably coordinating with its homolog MDM4 (MDMX) to inhibit p53. While the inhibition of p53 is often considered its most prominent role, accumulating evidence indicates that MDM2 also has p53-independent functions. Given its critical and diverse roles in cancer development, this Special Issue will highlight both clinical and basic research investigating MDM2. Although this Special Issue collaborates with the 10th International MDM2 Workshop, all relevant manuscripts are welcome, including research and review articles.

Guest Editors

Dr. Manabu Kurokawa

Dr. Tomoo Iwakuma

Dr. Koji Itahana

Dr. Rieko Ohki

Deadline for manuscript submissions

closed (10 December 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/164245

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)